RANIRani Therapeutics Holdings, Inc.vs its industry peers
A metric-by-metric comparison of Rani Therapeutics Holdings, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RANI본 종목 | $149M#6 | — | 3.8x#3 | 91.3x#2 | 58.9%#3 | 1.1%#9 | -2346.0%#10 | -75.6%#5 | — | — | 70.2%#2 | — |
| PVCT | — | — | — | — | -45.5%#11 | 15.6%#5 | -1575.3%#9 | — | — | — | — | — |
| QNRX | $483M#5 | — | 122.8x#6 | — | — | -75.6%#10 | — | -401.8%#8 | — | — | -20.1%#7 | — |
| QNTM | $44#9 | — | — | — | — | — | — | — | — | — | -81.7%#10 | — |
| QUCY | $116M#7 | — | 5.7x#4 | 216.0x#4 | -39.9%#9 | 24.9%#1 | -3005.0%#11 | -79.6%#6 | -203.8%#3 | — | -14.6%#5 | — |
| QURE | $2.8B#4 | — | 18.7x#5 | 173.3x#3 | -40.6%#10 | 16.9%#4 | -1151.4%#8 | -133.3%#7 | -263.3%#4 | — | 200.1%#1 | — |
| RADX | $4.2B#3 | — | — | 1152.1x#5 | 1114.3%#1 | 20.0%#2 | -1050.6%#6 | — | — | — | -75.2%#9 | — |
| RCKTW | $285414#8 | — | 0.0x#1 | — | — | 13.8%#6 | — | -60.5%#4 | — | — | -94.8%#11 | — |
| RDHL | $29.7B#1 | — | — | 3691.2x#6 | 23.2%#4 | -134.6%#13 | -181.7%#5 | — | — | — | -65.1%#8 | — |
| RDPTF | — | — | — | — | 1114.3%#1 | 20.0%#2 | -1050.6%#6 | — | — | — | — | — |
| RDY | $10.2B#2 | — | 2.6x#2 | 2.7x#1 | 13.8%#5 | — | 22.1%#2 | 17.0%#1 | — | — | -17.2%#6 | 0.8%#1 |
| REGN | — | 19.4x#1 | — | — | 1.0%#6 | 2.1%#8 | 24.9%#1 | 14.2%#2 | 9.4%#1 | — | 31.0%#3 | — |
| RFL | — | — | — | — | — | 11.3%#7 | -97196.7%#12 | -40.5%#3 | -43.7%#2 | — | 29.7%#4 | — |
| RGBP | — | — | — | — | 0.0%#7 | -90.7%#11 | -143.1%#3 | — | — | — | — | — |
| RGBPP | — | — | — | — | 0.0%#7 | -90.7%#11 | -143.1%#3 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice